Navigation Links
NeurogesX Reports First Quarter 2011 Results
Date:4/29/2011

SAN MATEO, Calif., April 29, 2011 /PRNewswire/ --

First Quarter 2011 Highlights:

  • Qutenza® (capsaicin) 8% patch purchased by 321 institutions, up from 239 in Q4 2010
  • Revenue of $3.2 million including $0.6 million U.S. Qutenza product revenue
  • Operational focus enables lower planned expense growth in 2011
  • Qutenza sales initiated in Poland and Czech Republic by Astellas
  • NGX-1998 Phase 2 clinical trial continues in postherpetic neuralgia (PHN) patients surpassing 65% enrollment

  • NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its first quarter ended March 31, 2011.

    Anthony DiTonno, President and CEO, commented, "We are now one full year into the U.S. launch of Qutenza.  We made progress in our goal of creating awareness of Qutenza among our target physician groups and in establishing a base of Qutenza treatment sites from which to build.   As we move into our second year post launch, we are focusing our sales organization on growing the number of sites of care that can optimally utilize Qutenza and building patient awareness and increased physician usage."

    Qutenza Launch MetricsNeurogesX is executing the U.S. launch strategy for Qutenza by establishing a national network of Qutenza referral sites (QPROs) and continuing to expand marketing activities to reach patients treated in the primary care setting.  Key Qutenza launch metrics as of March 31, 2011 were as follows:

  • Qutenza on formulary or available without restriction in 137 institutions as of March 31, 2011, up from 102 at year end 2010
  • 321 institutions purchased Qutenza through first quarter 2011, an increase of 34% from 239 in the fourth quarter 2010
  • Percentage of repeat institutional customers
    '/>"/>

  • SOURCE NeurogesX, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
    2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
    3. NeurogesX to Provide Qutenza® Launch Update
    4. NeurogesX to Present at Two February Investor Conferences
    5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
    6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
    7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
    8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
    9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
    10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
    11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
    (Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
    (Date:1/22/2015)... UPI ), a medical device company that develops, ... dysfunctions, today reported financial results for the fiscal 2015 ... for the Company,s Urgent ®  PC Neuromodulation System grew ... as compared to $3.9 million in the third quarter ...
    Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
    ... the Horizon 2" Special Session, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... present preclinical data for its product candidates,ENMD-2076, MKC-1, ... EntreMed,scientists and collaborators during the American Association for ...
    ... to improve ... management of risk for infection, BOSTON, April 10 ... lung transplantation at the,University of Pittsburgh Medical Center (UPMC) has ... with,microbial analysis of bronchoalveolar (BAL) fluids in immunosuppressed,patients, can help ...
    Cached Medicine Technology:EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting 2EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting 3Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients 2Prospective Microbial Analysis of Bronchoalveolar Lavage Fluids with Immune Function Testing Can Distinguish Between Fungal Colonization and Fungal Disease In Lung Transplant Recipients 3
    (Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
    (Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
    (Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
    (Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
    Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
    ... Kluger and co-workers from the Medical Oncology of Yale ... found that expression of high levels of TRAIL-R2 causes ... ,TRAIL receptors are cell surface receptors that ... expression was not associated with survival, high TRAIL-R2 expression ...
    ... in the summer months are quite difficult. Health problems due ... exhaustion and heat stroke. ,The recent issue of ... some tips to the elderly people that might make their ... to heading for the air conditioning, staying out of the ...
    ... suffer from the problem of excessive sweating even during ... relief from their condition. Researchers from Saint Louis University ... Botox (botulinum toxin type A) could be effective for ... long-term study of repeated treatment with Botox? (botulinum toxin ...
    ... no longer used to treat childhood asthma in Western// countries, ... routine cough in children with asthma. ,A study ... lack of good evidence for using Methylxanthines for children's cough ... author of the study Dr.Anne Chang, from Royal ...
    ... used to relieve anxiety symptoms, and valerian used for ... was reported in the first research study to be ... issue of the journal Medicine., ,The researchers Dr. ... California-San Francisco had performed an innovative Internet trial to ...
    ... one-day treatment with the anticancer drug carboplatin is as ... for a type of testicular cancer, according to results ... years standard care for stage 1 seminoma—a cancer of ... (hemi-castration) followed by three weeks radiotherapy. However, patients treated ...
    Cached Medicine News:Health News:New Discovery to Increase Survival of Breast cancer Patients 2Health News:Elderly People Needs To Tackle The Heat Effectively 2Health News:Good News For Those Suffering From Excessive Sweating 2Health News:Good News For Those Suffering From Excessive Sweating 3Health News:Study Warns About The Use Of Popular Asthma Drug To Stop Children's Coughs 2Health News:Herbal Remedies For Insomnia And Anxiety May Be Ineffective 2
    ... The Trans-Blot Plus cell offers rapid ... 26.5 x 28 cm blotting area. ... gels, such as those used with ... versatile tank transfer system provides uniform ...
    ... vacuum regulator, base with vacuum stage, porous ... assorted window gaskets, lid, instructions. The ... transfers DNA or RNA from an agarose ... generally requires only 90 min for transfer, ...
    ... proven electrophoretic transfer apparatus incorporating state-of-the-art plate electrodes ... allows for a very close positioning of the ... power source such as a battery charger, creates ... exceptionally rapid and exact electrophoretic transfer. ...
    ... proven electrophoretic transfer apparatus incorporating state-of-the-art plate electrodes ... allows for a very close positioning of the ... power source such as a battery charger, creates ... exceptionally rapid and exact electrophoretic transfer. ...
    Medicine Products: